Novo-Nordisk A/S (NVO)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 26, 2025 | $0.58 | 2025-08-18 | 2025-08-18 |
| April 8, 2025 | $1.14 | 2025-03-31 | 2025-03-31 |
| August 26, 2024 | $0.52 | 2024-08-16 | 2024-08-16 |
| April 2, 2024 | $0.93 | 2024-03-22 | 2024-03-25 |
| August 29, 2023 | $0.88 | 2023-08-18 | 2023-08-21 |
Dividends Summary
- Novo-Nordisk A/S has issued 33 dividend payments over the past 22 years
- The most recent dividend was paid 25 days ago, on August 26, 2025
- The highest dividend payed out to investors during this period was $3.10179 per share
- The average dividend paid during this period was $0.95 per share.
Company News
Eli Lilly is advancing its oral GLP-1 drug candidate with potential FDA fast-track review, signaling a potential breakthrough in diabetes and obesity treatment while expanding U.S. manufacturing capabilities.
Japan's auto-injectors market for GLP-1 receptor agonists is projected to grow from $137.7 million in 2025 to $292.9 million by 2038, driven by rising type 2 diabetes and obesity cases, and increasing demand for convenient at-home medication delivery methods.
German private bank Berenberg upgraded Novo Nordisk to 'buy', arguing that market expectations have reset and the stock is now more attractively valued after previous challenges in the weight loss drug market.
The FDA issued a warning letter to Hims & Hers Health for making misleading claims about its compounded semaglutide products, suggesting they are equivalent to FDA-approved drugs like Ozempic and Wegovy. The company must respond within 15 days or face potential legal actions.
Novo Nordisk and Eli Lilly have both cut prices on their weight-loss drugs Wegovy and Zepbound, respectively, in an apparent price war to attract more customers.